clonidine has been researched along with Multiple Sclerosis in 35 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multi-centre, double-blind study was carried out in 100 patients suffering from chronic spasticity due to multiple sclerosis to compare the effectiveness of tizanidine hydrochloride with that of baclofen." | 9.06 | Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. ( Boisson, D; Eyssette, M; Rohmer, F; Serratrice, G; Warter, JM, 1988) |
| "The anti-spastic effect of a new drug, tizanidine, was compared with that of baclofen in a double-blind clinical trial; 40 seriously handicapped patients with multiple sclerosis (MS) were randomly allocated treatment with one or the other drug for a 6-week period." | 9.06 | The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. ( Nordal, HJ; Oftedal, SI; Slettebø, M; Stien, R, 1987) |
| "A double-blind trial with two parallel groups was carried out to compare the antispastic effect and tolerability of a new muscle relaxant, tizanidine (DS 103-282), with those of baclofen in the treatment of spasticity due to multiple sclerosis." | 9.05 | A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. ( Muff, S; Smolenski, C; Smolenski-Kautz, S, 1981) |
| "Tizanidine hydrochloride, an alpha(2)-adrenergic receptor agonist, is a widely used medication for the treatment of muscle spasticity." | 8.84 | Update on tizanidine for muscle spasticity and emerging indications. ( Garay, E; Malanga, G; Reiter, RD, 2008) |
| "Tizanidine is an imidazoline central alpha(2)-adrenoceptor agonist widely used to manage spasticity secondary to conditions such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI)." | 8.84 | A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. ( Henney, HR; Kamen, L; Runyan, JD, 2008) |
| "Sixteen patients suffering from spasticity due to multiple sclerosis were treated with baclofen and tizanidine in a partially blind cross-over study." | 7.67 | Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. ( Hoogstraten, MC; Minderhoud, JM; van der Ploeg, RJ; van Marle, S; vd Burg, W; Vreeling, A, 1988) |
| "Tizanidine HCl is an alpha2 adrenergic agonist indicated for treating spasticity due to MS or spinal cord injury." | 6.75 | Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety. ( Auriel, E; Karni, A; Vakhapova, V, 2010) |
| "Tizanidine treatment reduced muscle tone significantly, as shown by improved Ashworth scores and increased knee swing amplitude recorded by the pendulum test, both of which correlated significantly with plasma concentration." | 6.68 | Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. ( Cohen, JA; Francis, GS; Hudson, S; Lindsey, JW; Lynch, SG; Mass, MK; Nance, PW; O'Connor, P; Schapiro, RT; Shellenberger, K; Sheremata, WA; Vollmer, T; Whitham, R, 1997) |
| "Tizanidine is a well-tolerated and effective drug for symptomatic treatment of spasticity." | 6.67 | A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. ( , 1994) |
| " All efficacy parameters were evaluated by the physician/assessor, and the physician/prescriber was responsible for all dosage adjustments." | 6.67 | Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. ( Birnbaum, G; Carter, JL; Greenstein, J; Lublin, FD; Smith, C, 1994) |
| "Current drugs used as antispastic agents include Dantrolene Sodium, Baclofen and Diazepam." | 6.66 | Treatment of spasticity with tizanidine in multiple sclerosis. ( Barkas, WJ; Bouchard, S; Francis, GS; Gendron, D; Lapierre, Y; Tansey, C, 1987) |
| "Tizanidine (Sirdalud) was compared to baclofen (Lioresal) in a randomized, double-blind, cross-over trial." | 6.66 | Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. ( Bass, B; Bouchard, S; Cameron, MG; Ebers, GC; Hader, W; Noseworthy, JH; Rice, GP; Weinshenker, B, 1988) |
| "A multi-centre, double-blind study was carried out in 100 patients suffering from chronic spasticity due to multiple sclerosis to compare the effectiveness of tizanidine hydrochloride with that of baclofen." | 5.06 | Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. ( Boisson, D; Eyssette, M; Rohmer, F; Serratrice, G; Warter, JM, 1988) |
| "In a double-blind comparative study, the therapeutic efficacy and safety of three centrally effective antispasmodics (Tetrazepam, Baclofen and Tizanidine) in patients suffering from multiple sclerosis with spastic motor disturbances of the lower extremities was to be examined." | 5.06 | [Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities]. ( Paulig, M; Pellkofer, M, 1989) |
| "The anti-spastic effect of a new drug, tizanidine, was compared with that of baclofen in a double-blind clinical trial; 40 seriously handicapped patients with multiple sclerosis (MS) were randomly allocated treatment with one or the other drug for a 6-week period." | 5.06 | The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. ( Nordal, HJ; Oftedal, SI; Slettebø, M; Stien, R, 1987) |
| "A double-blind trial with two parallel groups was carried out to compare the antispastic effect and tolerability of a new muscle relaxant, tizanidine (DS 103-282), with those of baclofen in the treatment of spasticity due to multiple sclerosis." | 5.05 | A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. ( Muff, S; Smolenski, C; Smolenski-Kautz, S, 1981) |
| "Tizanidine hydrochloride, an alpha(2)-adrenergic receptor agonist, is a widely used medication for the treatment of muscle spasticity." | 4.84 | Update on tizanidine for muscle spasticity and emerging indications. ( Garay, E; Malanga, G; Reiter, RD, 2008) |
| "Tizanidine is an imidazoline central alpha(2)-adrenoceptor agonist widely used to manage spasticity secondary to conditions such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI)." | 4.84 | A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. ( Henney, HR; Kamen, L; Runyan, JD, 2008) |
| "Sixteen patients suffering from spasticity due to multiple sclerosis were treated with baclofen and tizanidine in a partially blind cross-over study." | 3.67 | Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. ( Hoogstraten, MC; Minderhoud, JM; van der Ploeg, RJ; van Marle, S; vd Burg, W; Vreeling, A, 1988) |
| "The time-course of plasma concentrations of the antispasticity agent tizanidine were measured by a specific radioimmune-assay in six adults who had severe spasticity due to multiple sclerosis." | 3.66 | Tizanidine--initial pharmacokinetic studies in patients with spasticity. ( Eadie, MJ; Heazlewood, V; Maruff, P; Symoniw, P, 1983) |
| "We aimed to determine whether antispasticity treatment history influenced the efficacy and safety of add-on THC:CBD oromucosal spray in MS spasticity patients." | 2.82 | Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity. ( Álvarez-Ossorio, L; Haupts, M; Jonas, A; Vila, C; Witte, K, 2016) |
| "Tizanidine HCl is an alpha2 adrenergic agonist indicated for treating spasticity due to MS or spinal cord injury." | 2.75 | Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety. ( Auriel, E; Karni, A; Vakhapova, V, 2010) |
| " To reduce muscle tension, 34 patients of the main group received tizanidine with the modified release of active substance (sirdalud MR) in dosage one capsule (6 mg) per day." | 2.75 | [The use of sirdalud MR in patients with multiple sclerosis]. ( Batysheva, TT; Boĭko, AN; Kamchatnov, PR; Petrov, SV; Popova, NF; Zaĭtsev, KA, 2010) |
| "Tizanidine treatment reduced muscle tone significantly, as shown by improved Ashworth scores and increased knee swing amplitude recorded by the pendulum test, both of which correlated significantly with plasma concentration." | 2.68 | Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. ( Cohen, JA; Francis, GS; Hudson, S; Lindsey, JW; Lynch, SG; Mass, MK; Nance, PW; O'Connor, P; Schapiro, RT; Shellenberger, K; Sheremata, WA; Vollmer, T; Whitham, R, 1997) |
| "Tizanidine is a well-tolerated and effective drug for symptomatic treatment of spasticity." | 2.67 | A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. ( , 1994) |
| " All efficacy parameters were evaluated by the physician/assessor, and the physician/prescriber was responsible for all dosage adjustments." | 2.67 | Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. ( Birnbaum, G; Carter, JL; Greenstein, J; Lublin, FD; Smith, C, 1994) |
| "Tizanidine (Sirdalud) was compared to baclofen (Lioresal) in a randomized, double-blind, cross-over trial." | 2.66 | Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. ( Bass, B; Bouchard, S; Cameron, MG; Ebers, GC; Hader, W; Noseworthy, JH; Rice, GP; Weinshenker, B, 1988) |
| "Current drugs used as antispastic agents include Dantrolene Sodium, Baclofen and Diazepam." | 2.66 | Treatment of spasticity with tizanidine in multiple sclerosis. ( Barkas, WJ; Bouchard, S; Francis, GS; Gendron, D; Lapierre, Y; Tansey, C, 1987) |
| " The study consisted of 4 parts: I, double-blind cross-over trial at maximal dosage 10 mg/day in 13 patients; II, open trial at maximal dosage 32 mg/day in 10 patients; III, long-term medication at dosage 32 mg/day for 6-15 months in 4 patients; IV, single dose (12 mg) administration in 3 patients." | 2.65 | Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis. ( Gransberg, L; Knutsson, E; Mårtensson, A, 1982) |
| "Percentages of improved patients' spasticity scale, mild adverse effect and severe adverse effect were extracted as outcomes." | 2.58 | A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis. ( Fu, X; Li, J; Li, M; Ma, Q; Wang, C; Wang, Y; Wu, H; Yang, W, 2018) |
| "The available studies on spasticity treatment offer some insight to guide clinical practice but are of variable methodological quality." | 2.53 | Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. ( Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P, 2016) |
| "The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol." | 2.48 | [Pharmacological treatment of spasticity in multiple sclerosis]. ( Heinzlef, O; Monteil-Roch, I, 2012) |
| " Practical advice on tizanidine dosing and/or switching between formulations is provided." | 2.44 | A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients. ( Henney, HR; Runyan, JD, 2008) |
| "Among the more common symptoms is spasticity." | 2.41 | Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001) |
| "With the introduction of the antispasticity agent, tizanidine hydrochloride (Zanaflex), physicians have requested information about the optimal way to switch appropriate patients from baclofen to tizanidine." | 2.40 | An approach to switching patients from baclofen to tizanidine. ( Brenner, R; Hyman, N; Knobler, R; O'Brien, M; Stephan, T, 1998) |
| " It has low oral bioavailability and short halflife." | 1.56 | Optimization of Microemulgel for Tizanidine Hydrochloride. ( Brahmane, S; Chabukswar, A; Jagdale, S, 2020) |
| "Treatment of spasticity includes oral and intrathecal anti-spastic drugs, muscle injections with relaxant agents, physical therapy, electrical and magnetic stimulation and peripheral nerve stimulation, alone or in various combinations." | 1.56 | Italian consensus on treatment of spasticity in multiple sclerosis. ( Centonze, D; Comi, G; Leocani, L; Otero-Romero, S; Solari, A, 2020) |
| "Twelve spastic patients received single oral doses of a new anti-spastic drug DS103-282 (Sandoz) 6 mg, baclofen 20 mg, and placebo on three separate days." | 1.26 | Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity. ( Hassan, N; McLellan, DL, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (37.14) | 18.7374 |
| 1990's | 7 (20.00) | 18.2507 |
| 2000's | 4 (11.43) | 29.6817 |
| 2010's | 8 (22.86) | 24.3611 |
| 2020's | 3 (8.57) | 2.80 |
| Authors | Studies |
|---|---|
| Comi, G | 2 |
| Solari, A | 1 |
| Leocani, L | 1 |
| Centonze, D | 1 |
| Otero-Romero, S | 2 |
| Jones, É | 1 |
| Vlachou, S | 1 |
| Lee, BS | 1 |
| Jones, J | 1 |
| Lang, M | 1 |
| Achey, R | 1 |
| Dai, L | 1 |
| Lobel, DA | 1 |
| Nagel, SJ | 1 |
| Machado, AG | 1 |
| Bethoux, F | 1 |
| Fu, X | 1 |
| Wang, Y | 1 |
| Wang, C | 1 |
| Wu, H | 1 |
| Li, J | 1 |
| Li, M | 1 |
| Ma, Q | 1 |
| Yang, W | 1 |
| Jagdale, S | 1 |
| Brahmane, S | 1 |
| Chabukswar, A | 1 |
| Haupts, M | 1 |
| Vila, C | 1 |
| Jonas, A | 1 |
| Witte, K | 1 |
| Álvarez-Ossorio, L | 1 |
| Sastre-Garriga, J | 1 |
| Hartung, HP | 1 |
| Soelberg Sørensen, P | 1 |
| Thompson, AJ | 1 |
| Vermersch, P | 1 |
| Gold, R | 1 |
| Montalban, X | 1 |
| Malanga, G | 1 |
| Reiter, RD | 1 |
| Garay, E | 1 |
| Vakhapova, V | 1 |
| Auriel, E | 1 |
| Karni, A | 1 |
| Batysheva, TT | 1 |
| Popova, NF | 1 |
| Petrov, SV | 1 |
| Kamchatnov, PR | 1 |
| Zaĭtsev, KA | 1 |
| Boĭko, AN | 1 |
| Ho, JK | 1 |
| Sadiq, SA | 1 |
| Heinzlef, O | 1 |
| Monteil-Roch, I | 1 |
| Kamen, L | 1 |
| Henney, HR | 2 |
| Runyan, JD | 2 |
| Heazlewood, V | 1 |
| Symoniw, P | 1 |
| Maruff, P | 1 |
| Eadie, MJ | 1 |
| Smolenski, C | 1 |
| Muff, S | 1 |
| Smolenski-Kautz, S | 1 |
| Knutsson, E | 1 |
| Mårtensson, A | 1 |
| Gransberg, L | 1 |
| Hassan, N | 1 |
| McLellan, DL | 1 |
| Zoukos, Y | 1 |
| Thomaides, T | 1 |
| Mathias, CJ | 1 |
| Cuzner, ML | 1 |
| Smith, C | 1 |
| Birnbaum, G | 1 |
| Carter, JL | 1 |
| Greenstein, J | 1 |
| Lublin, FD | 1 |
| Khan, OA | 1 |
| Olek, MJ | 1 |
| Nance, PW | 1 |
| Sheremata, WA | 1 |
| Lynch, SG | 1 |
| Vollmer, T | 1 |
| Hudson, S | 1 |
| Francis, GS | 2 |
| O'Connor, P | 1 |
| Cohen, JA | 1 |
| Schapiro, RT | 2 |
| Whitham, R | 1 |
| Mass, MK | 1 |
| Lindsey, JW | 1 |
| Shellenberger, K | 1 |
| Brenner, R | 1 |
| Hyman, N | 1 |
| Knobler, R | 1 |
| O'Brien, M | 1 |
| Stephan, T | 1 |
| Gerstenbrand, F | 1 |
| Lorincz, A | 1 |
| Ludin, HP | 1 |
| Ringwald, E | 1 |
| Pellkofer, M | 1 |
| Paulig, M | 1 |
| Rice, GP | 2 |
| Eyssette, M | 1 |
| Rohmer, F | 1 |
| Serratrice, G | 1 |
| Warter, JM | 1 |
| Boisson, D | 1 |
| Bass, B | 1 |
| Weinshenker, B | 1 |
| Noseworthy, JH | 1 |
| Cameron, MG | 1 |
| Hader, W | 1 |
| Bouchard, S | 2 |
| Ebers, GC | 1 |
| Hoogstraten, MC | 1 |
| van der Ploeg, RJ | 1 |
| vd Burg, W | 1 |
| Vreeling, A | 1 |
| van Marle, S | 1 |
| Minderhoud, JM | 1 |
| Cendrowski, W | 1 |
| Stien, R | 1 |
| Nordal, HJ | 1 |
| Oftedal, SI | 1 |
| Slettebø, M | 1 |
| Lapierre, Y | 1 |
| Tansey, C | 1 |
| Gendron, D | 1 |
| Barkas, WJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.[NCT05912595] | 36 participants (Anticipated) | Interventional | 2023-05-18 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for clonidine and Multiple Sclerosis
| Article | Year |
|---|---|
A Critical Review of the Role of the Cannabinoid Compounds Δ
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Baclofen; Cannabidiol; Clinical Trials as Topic; Clon | 2020 |
A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis.
Topics: Baclofen; Botulinum Toxins, Type A; Cannabinoids; Clonidine; Diazepam; Humans; Multiple Sclerosis; M | 2018 |
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diaze | 2016 |
Update on tizanidine for muscle spasticity and emerging indications.
Topics: Adrenergic alpha-2 Receptor Agonists; Clonidine; Dose-Response Relationship, Drug; Humans; Low Back | 2008 |
[Pharmacological treatment of spasticity in multiple sclerosis].
Topics: Algorithms; Amines; Baclofen; Botulinum Toxins, Type A; Clonidine; Cyclohexanecarboxylic Acids; Dant | 2012 |
A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.
Topics: Brain Injuries; Clonidine; Disease Progression; Drug Interactions; Female; Humans; Middle Aged; Mult | 2008 |
A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients.
Topics: Chemistry, Pharmaceutical; Ciprofloxacin; Clonidine; Dose-Response Relationship, Drug; Drug Interact | 2008 |
An approach to switching patients from baclofen to tizanidine.
Topics: Baclofen; Clinical Competence; Clonidine; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Mus | 1998 |
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin | 2001 |
13 trials available for clonidine and Multiple Sclerosis
| Article | Year |
|---|---|
Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Topics: Adult; Baclofen; Cannabidiol; Clonidine; Dronabinol; Drug Combinations; Female; Humans; Male; Middle | 2016 |
Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.
Topics: Administration, Sublingual; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adult; | 2010 |
[The use of sirdalud MR in patients with multiple sclerosis].
Topics: Adult; Clonidine; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Relaxants, Central; Muscle W | 2010 |
A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Topics: Adult; Aged; Baclofen; Chronic Disease; Clinical Trials as Topic; Clonidine; Double-Blind Method; Fe | 1981 |
Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis.
Topics: Adult; Aged; Clinical Trials as Topic; Clonidine; Dose-Response Relationship, Drug; Double-Blind Met | 1982 |
Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
Topics: Adolescent; Adult; Aged; Clonidine; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple | 1994 |
A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Clonidine; Double-Blind Method; Female; Humans; | 1994 |
Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis.
Topics: Adrenergic alpha-Agonists; Canada; Cardiovascular System; Clonidine; Dose-Response Relationship, Dru | 1997 |
[Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities].
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Baclofen; Benzodiazepines; Benzodiazepinones; Clinical | 1989 |
Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
Topics: Adult; Aged; Baclofen; Clinical Trials as Topic; Clonidine; Double-Blind Method; Female; Humans; Mal | 1988 |
Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis.
Topics: Adult; Aged; Baclofen; Brain; Clonidine; Dose-Response Relationship, Drug; Female; Humans; Male; Mid | 1988 |
The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen.
Topics: Adult; Aged; Baclofen; Clinical Trials as Topic; Clonidine; Double-Blind Method; Drug Tolerance; Fem | 1987 |
Treatment of spasticity with tizanidine in multiple sclerosis.
Topics: Adolescent; Adult; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; | 1987 |
13 other studies available for clonidine and Multiple Sclerosis
| Article | Year |
|---|---|
Italian consensus on treatment of spasticity in multiple sclerosis.
Topics: Baclofen; Botulinum Toxins; Clonidine; Consensus; Disease Management; Gabapentin; Humans; Injections | 2020 |
Early outcomes after intrathecal baclofen therapy in ambulatory patients with multiple sclerosis.
Topics: Administration, Oral; Aged; Ambulatory Care; Baclofen; Clonidine; Drug Therapy, Combination; Female; | 2018 |
Optimization of Microemulgel for Tizanidine Hydrochloride.
Topics: Administration, Cutaneous; Animals; Biological Availability; Cells, Cultured; Chickens; Clonidine; D | 2020 |
Use of intrathecal clonidine in patients with multiple sclerosis or spastic paraparesis.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Clonidine; Female; Humans; Injections, Spinal; Male; Mi | 2012 |
Tizanidine--initial pharmacokinetic studies in patients with spasticity.
Topics: Adult; Clonidine; Female; Half-Life; Humans; Kinetics; Male; Middle Aged; Multiple Sclerosis; Muscle | 1983 |
Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.
Topics: Adolescent; Adult; Aged; Baclofen; Clonidine; Double-Blind Method; Electromyography; Female; Hemiple | 1980 |
High beta-adrenoceptor density on peripheral blood mononuclear cells in progressive multiple sclerosis: a manifestation of autonomic dysfunction?
Topics: Adult; Aged; Autonomic Nervous System; Autonomic Nervous System Diseases; Clonidine; Epinephrine; Fe | 1994 |
Clonidine in the treatment of spasticity in patients with multiple sclerosis.
Topics: Adult; Clonidine; Female; Humans; Male; Multiple Sclerosis; Muscle Spasticity | 1995 |
A new drug to treat spasticity?
Topics: Clonidine; Drug Approval; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Spinal Cord Injurie | 1996 |
[Long-term treatment with an imidazoline derivative (DS 103--282) (author's transl)].
Topics: Arm; Clonidine; Female; Humans; Leg; Male; Multiple Sclerosis; Muscle Spasticity; Paralysis; Urinati | 1979 |
Tizanidine vs. baclofen in the treatment of spasticity in patients with multiple sclerosis.
Topics: Baclofen; Clonidine; Drug Tolerance; Humans; Multiple Sclerosis; Muscle Spasticity | 1989 |
Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients.
Topics: Adult; Aged; Baclofen; Clonidine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Age | 1988 |
[Long-term treatment of spasticity with tisanidine (sirdulad) in 2 cases of multiple sclerosis].
Topics: Clonidine; Female; Humans; Leg; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Time Factors | 1987 |